Selskabsvedtægter for Genmab A/S
December 21, 2017 08:27 ET
|
Genmab A/S
Selskabsvedtægter for Genmab A/S dateret den 15. december 2017 er blevet offentliggjort. Selskabsvedtægterne er tilgængelige på Genmabs hjemmeside:...
Articles of Association for Genmab A/S
December 21, 2017 08:27 ET
|
Genmab A/S
Genmab A/S has published its Articles of Association dated December 15, 2017. The Articles of Association can be found on Genmab’s website: http://ir.genmab.com/releases.cfm
Contact:
Rachel...
Grant of Restricted Stock Units to Board Members, Management and Employees and Grant of Warrants to Management and Employees in Genmab
December 15, 2017 13:52 ET
|
Genmab A/S
Company Announcement
Copenhagen, Denmark; December 15, 2017 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that at a board meeting the board decided to grant 49,680 restricted stock units...
Genmab’s 2017 R&D Update
December 11, 2017 06:39 ET
|
Genmab A/S
Media Release
R&D Update to be held today in Atlanta, Georgia
Key Opinion Leaders to discuss daratumumab and tisotumab vedotin data
Discussion of Genmab’s pipeline, 2017 progress...
Genmab to Hold 2017 R&D Update
December 04, 2017 11:01 ET
|
Genmab A/S
Media Release
R&D Update to be held live in Atlanta, Georgia
Key Opinion Leaders to discuss daratumumab and tisotumab vedotin data
Discussion of Genmab’s pipeline, 2017 progress...
Genmab Achieves USD 20 Million Milestone in Daratumumab Collaboration with Janssen and Updates Financial Guidance
November 29, 2017 15:41 ET
|
Genmab A/S
Company Announcement
Genmab to receive USD 20 million milestone payment from Janssen
Milestone triggered by progress in the Phase III study of daratumumab in combination with...
Genmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in Front Line Multiple Myeloma
November 21, 2017 11:12 ET
|
Genmab A/S
Company Announcement
sBLA submitted to U.S. FDA for daratumumab in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma...
Data from Phase III ALCYONE Study of Daratumumab Accepted for Oral Presentation at Annual Meeting of the American Society of Hematology
November 21, 2017 09:34 ET
|
Genmab A/S
Media Release
Late-breaking abstract accepted for oral presentation
Data from Phase III ALCYONE study of daratumumab in combination with bortezomib, melphalan and prednisone in front line...
Genmab Announces European Regulatory Submission for Daratumumab in Front Line Multiple Myeloma
November 21, 2017 06:58 ET
|
Genmab A/S
Company Announcement
Application to broaden label for daratumumab in front line multiple myeloma submitted to EMA
Submission based on data from Phase III ALCYONE study
Genmab to...
Genmab Achieves USD 50 Million Sales Milestone in DARZALEX® (daratumumab) Collaboration with Janssen
November 16, 2017 21:30 ET
|
Genmab A/S
Company Announcement
Genmab to receive milestone payment of USD 50 million in DARZALEX collaboration
Milestone triggered by sales of DARZALEX reaching USD 1 billion in a calendar...